Limb-girdle muscular dystrophies - International collaborations for translational research

Nature Reviews Neurology

Volumn 12, Issue 5, 2016, Pages 294-309

  Thompson, Rachel ^a   Straub, Volker ^a  

^a NEWCASTLE UNIVERSITY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

FUKUTIN RELATED PROTEIN;

ALLELE; CLINICAL FEATURE; DIAGNOSTIC TEST; DISEASE CLASSIFICATION; EXOME; FKRP GENE; GENE LOCUS; GENE MAPPING; GENE SEQUENCE; GENETIC ASSOCIATION; GENETIC CODE; GENETIC DISORDER; GLYCOSYLATION; HUMAN; HUMAN GENOME PROJECT; LIMB GIRDLE MUSCULAR DYSTROPHY; MUSCLE STRENGTH; NEXT GENERATION SEQUENCING; PATHOPHYSIOLOGY; PHENOTYPE; PRIORITY JOURNAL; REVIEW; TRANSLATIONAL RESEARCH; CLASSIFICATION; GENETICS; GENOMICS; INTERNATIONAL COOPERATION; INTERSECTORAL COLLABORATION;

GENOMICS; HUMANS; INTERNATIONAL COOPERATION; INTERSECTORAL COLLABORATION; MUSCULAR DYSTROPHIES, LIMB-GIRDLE; TRANSLATIONAL MEDICAL RESEARCH;

EID: 84962054136     PISSN: 17594758     EISSN: 17594766     Source Type: Journal    
DOI: 10.1038/nrneurol.2016.35     Document Type: Review

References (82)

1. Walton, J. N. & Nattrass, F. J. On the classification, natural history and treatment of the myopathies. Brain 77, 169-231 (1954).
2. Fanin, M., Nascimbeni, A. C., Fulizio, L. & Angelini, C. The frequency of limb girdle muscular dystrophy 2A in northeastern Italy. Neuromuscul. Disord. 15, 218-224 (2005).
3. Narayanaswami, P. et al. Evidence-based guideline summary: diagnosis and treatment of limb-girdle and distal dystrophies: report of the Guideline Development Subcommittee of the American Academy of Neurology and the Practice Issues Review Panel of the American Association of Neuromuscular and Electrodiagnostic Medicine. Neurology 83, 1453-1463 (2014).
4. Nigro, V. & Savarese, M. Genetic basis of limb-girdle muscular dystrophies: the 2014 update. Acta Myol. 33, 1-12 (2014).
5. Murphy, A. P. & Straub, V. The classification, natural history and treatment of the limb girdle muscular dystrophies. J. Neuromuscul. Dis. 2 (Suppl. 2), 7-19 (2015).
6. Hauser, M. A. et al. Myotilin is mutated in limb girdle muscular dystrophy 1A. Hum. Mol. Genet. 9, 2141-2147 (2000).
7. Muchir, A. et al. Identification of mutations in the gene encoding lamins A/C in autosomal dominant limb girdle muscular dystrophy with atrioventricular conduction disturbances (LGMD1B). Hum. Mol. Genet. 9, 1453-1459 (2000).
8. Minetti, C. et al. Mutations in the caveolin-3 gene cause autosomal dominant limb-girdle muscular dystrophy. Nat. Genet. 18, 365-368 (1998).
9. McNally, E. Caveolin-3 in muscular dystrophy. Hum. Mol. Genet. 7, 871-877 (1998).
10. Sarparanta, J. et al. Mutations affecting the cytoplasmic functions of the co-chaperone DNAJB6 cause limb-girdle muscular dystrophy. Nat. Genet. 44, 450-455 (2012).
11. Harms, M. B. et al. Exome sequencing reveals DNAJB6 mutations in dominantly-inherited myopathy. Ann. Neurol. 71, 407-416 (2012).
12. Greenberg, S. A. et al. Etiology of limb girdle muscular dystrophy 1D/1E determined by laser capture microdissection proteomics. Ann. Neurol. 71, 141-145 (2012).
13. Hedberg, C., Melberg, A., Kuhl, A., Jenne, D. & Oldfors, A. Autosomal dominant myofibrillar myopathy with arrhythmogenic right ventricular cardiomyopathy 7 is caused by a DES mutation. Eur. J. Hum. Genet. 20, 984-985 (2012).
14. Melia, M. J. et al. Limb-girdle muscular dystrophy 1F is caused by a microdeletion in the transportin 3 gene. Brain 136, 1508-1517 (2013).
15. Vieira, N. M. et al. A defect in the RNA-processing protein HNRPDL causes limb-girdle muscular dystrophy 1G (LGMD1G). Hum. Mol. Genet. 23, 4103-4110 (2014).
16. Beckmann, J. S. et al. A gene for limb-girdle muscular dystrophy maps to chromosome 15 by linkage. C. R. Acad. Sci. III 312, 141-148 (1991).
17. Richard, I. et al. Mutations in the proteolytic enzyme calpain 3 cause limb-girdle muscular dystrophy type 2A. Cell 81, 27-40 (1995).
18. Bashlr, R. et al. A gene for autosomal recessive limb-girdle muscular dystrophy maps to chromosome 2p. Hum. Mol. Genet. 3, 455-457 (1994).
19. Liu, J. et al. Dysferlin, a novel skeletal muscle gene, is mutated in Miyoshi myopathy and limb girdle muscular dystrophy. Nat. Genet. 20, 31-36 (1998).
20. Bashir, R. et al. A gene related to Caenorhabditis elegans spermatogenesis factor fer-1 is mutated in limb-girdle muscular dystrophy type 2B. Nat. Genet. 20, 37-42 (1998).
21. Azlbi, K. et al. Severe childhood autosomal recessive muscular dystrophy with the deficiency of the 50 kDa dystrophin-associated glycoprotein maps to chromosome 13q12. Hum. Mol. Genet. 2, 1423-1428 (1993).
22. Noguchi, S. et al. Mutations in the dystrophin-associated protein γ-sarcoglycan in chromosome 13 muscular dystrophy. Science 270, 819-822 (1995).
23. Roberds, S. L. et al. Missense mutations in the adhalin gene linked to autosomal recessive muscular dystrophy. Cell 78, 625-633 (1994).
24. Piccolo, F. et al. Primary adhalinopathy: a common cause of autosomal recessive muscular dystrophy of variable severity. Nat. Genet. 10, 243-245 (1995).
25. Lim, L. E. et al. β-sarcoglycan: characterization and role in limb-girdle muscular dystrophy linked to 4q12. Nat. Genet. 11, 257-265 (1995).
26. Bönnemann, C. G. et al. β-sarcoglycan (A3b) mutations cause autosomal recessive muscular dystrophy with loss of the sarcoglycan complex. Nat. Genet. 11, 266-273 (1995).
27. Passos-Bueno, M. Linkage analysis in autosomal recessive limb-girdle muscular dystrophy (AR LGMD) maps a sixth form to 5q33-34 (LGMD2F) and indicates that there is at least one more subtype of AR LGMD. Hum. Mol. Genet. 5, 815-820 (1996).
28. Nigro, V. et al. Autosomal recessive limb-girdle muscular dystrophy, LGMD2F, is caused by a mutation in the δ-sarcoglycan gene. Nat. Genet. 14, 195-198 (1996).
29. Moreira, E. S. et al. Limb-girdle muscular dystrophy type 2G is caused by mutations in the gene encoding the sarcomeric protein telethonin. Nat. Genet. 24, 163-166 (2000).
30. Weiler, T. et al. A gene for autosomal recessive limb-girdle muscular dystrophy in Manitoba Hutterites maps to chromosome region 9q31-q33: evidence for another limb-girdle muscular dystrophy locus. Am. J. Hum. Genet. 63, 140-147 (1998).
31. Frosk, P. et al. Limb-girdle muscular dystrophy type 2H associated with mutation in TRIM32, a putative E3-ubiquitin-ligase gene. Am. J. Hum. Genet. 70, 663-672 (2002).
32. Brockington, M. et al. Mutations in the fukutin-related protein gene (FKRP) identify limb girdle muscular dystrophy 2I as a milder allelic variant of congenital muscular dystrophy MDC1C. Hum. Mol. Genet. 10, 2851-2859 (2001).
33. Hackman, P. et al. Tibial muscular dystrophy is a titinopathy caused by mutations in TTN, the gene encoding the giant skeletal-muscle protein titin. Am. J. Hum. Genet. 71, 492-500 (2002).
34. Balci, B. et al. An autosomal recessive limb girdle muscular dystrophy (LGMD2) with mild mental retardation is allelic to Walker-Warburg syndrome (WWS) caused by a mutation in the POMT1 gene. Neuromuscul. Disord. 15, 271-275 (2005).
35. Jarry, J. et al. A novel autosomal recessive limb-girdle muscular dystrophy with quadriceps atrophy maps to 11p13-p12. Brain 130, 368-380 (2007).
36. Bolduc, V. et al. Recessive mutations in the putative calcium-activated chloride channel anoctamin 5 cause proximal LGMD2L and distal MMD3 muscular dystrophies. Am. J. Hum. Genet. 86, 213-221 (2010).
37. Murakami, T. et al. Fukutin gene mutations cause dilated cardiomyopathy with minimal muscle weakness. Ann. Neurol. 60, 597-602 (2006).
38. Godfrey, C. et al. Fukutin gene mutations in steroid-responsive limb girdle muscular dystrophy. Ann. Neurol. 60, 603-610 (2006).
39. Biancheri, R. et al. POMT2 gene mutation in limb-girdle muscular dystrophy with inflammatory changes. Biochem. Biophys. Res. Commun. 363, 1033-1037 (2007).
40. Clement, E. M. et al. Mild POMGnT1 mutations underlie a novel limb-girdle muscular dystrophy variant. Arch. Neurol. 65, 137-141 (2008).
41. Raducu, M., Baets, J., Fano, O., Van Coster, R. & Cruces, J. Promoter alteration causes transcriptional repression of the POMGNT1 gene in limb-girdle muscular dystrophy type 2O. Eur. J. Hum. Genet. 20, 945-952 (2012).
42. Hara, Y. et al. A dystroglycan mutation associated with limb-girdle muscular dystrophy. N. Engl. J. Med. 364, 939-946 (2011).
43. Gundesli, H. et al. Mutation in exon 1f of PLEC, leading to disruption of plectin isoform 1f, causes autosomal-recessive limb-girdle muscular dystrophy. Am. J. Hum. Genet. 87, 834-841 (2010).
44. Cetin, N. et al. A novel desmin mutation leading to autosomal recessive limb-girdle muscular dystrophy: distinct histopathological outcomes compared with desminopathies. J. Med. Genet. 50, 437-443 (2013).
45. Bögershausen, N. et al. Recessive TRAPPC11 mutations cause a disease spectrum of limb girdle muscular dystrophy and myopathy with movement disorder and intellectual disability. Am. J. Hum. Genet. 93, 181-190 (2013).
46. Carss, K. J. et al. Mutations in GDP-mannose pyrophosphorylase b cause congenital and limb-girdle muscular dystrophies associated with hypoglycosylation of α-dystroglycan. Am. J. Hum. Genet. 93, 29-41 (2013).
47. Tasca, G. et al. Limb-girdle muscular dystrophy with α-dystroglycan deficiency and mutations in the ISPD gene. Neurology 80, 963-965 (2013).
48. Preisler, N. et al. Late-onset Pompe disease is prevalent in unclassified limb-girdle muscular dystrophies. Mol. Genet. Metab. 110, 287-289 (2013).
49. Chardon, J. W. et al. LIMS2 mutations are associated with a novel muscular dystrophy, severe cardiomyopathy and triangular tongues. Clin. Genet. 88, 558-5564 (2015).
50. S201F causes muscular dystrophy and arrhythmia by affecting protein trafficking. J. Clin. Invest. 126, 239-253 (2016).
51. Wells, L. The O-mannosylation pathway: glycosyltransferases and proteins implicated in congenital muscular dystrophy. J. Biol. Chem. 288, 6930-6935 (2013).
52. Endo, T. Glycobiology of α-dystroglycan and muscular dystrophy. J. Biochem. 157, 1-12 (2015).
53. Yoshida-Moriguchi, T. & Campbell, K. P. Matriglycan: a novel polysaccharide that links dystroglycan to the basement membrane. Glycobiology 25, 702-713 (2015).
54. Vissing, J., Sveen, M. L. & Duno, M. O.22 dominant inheritance of limb girdle muscular dystrophy type 2A. Neuromuscul. Disord. 21, 750 (2011).
55. Ghaoui, R. et al. Use of whole-exome sequencing for diagnosis of limb-girdle muscular dystrophy: outcomes and lessons learned. JAMA Neurol. 72, 1424-1432 (2015).
56. Biancalana, V. & Laporte, J. Diagnostic use of massively parallel sequencing in neuromuscular diseases: towards an integrated diagnosis. J. Neuromuscul. Dis. 2, 193-203 (2015).
57. Chae, J. H. et al. Utility of next generation sequencing in genetic diagnosis of early onset neuromuscular disorders. J. Med. Genet. 52, 208-216 (2015).
58. Ankala, A. et al. A comprehensive genomic approach for neuromuscular diseases gives a high diagnostic yield. Ann. Neurol. 77, 206-214 (2014).
59. Cabrera-Serrano, M. et al. Expanding the phenotype of GMPPB mutations. Brain 138, 836-844 (2015).
60. Lek, M. & MacArthur, D. The challenge of next generation sequencing in the context of neuromuscular diseases. J. Neuromuscul. Dis. 1, 135-149 (2014).
61. Boycott, K. M., Dyment, D. A., Sawyer, S. L., Vanstone, M. R. & Beaulieu, C. L. Identification of genes for childhood heritable diseases. Annu. Rev. Med. 65, 19-31 (2014).
62. Rodger, S. et al. The TREAT-NMD care and trial site registry: an online registry to facilitate clinical research for neuromuscular diseases. Orphanet J. Rare Dis. 8, 171 (2013).
63. Bushby, K., Lynn, S. & Straub, T. Collaborating to bring new therapies to the patient - the TREAT-NMD model. Acta Myol. 28, 12-15 (2009).
64. Knoppers, B. M., Harris, J. R., Budin-Ljøsne, I. & Dove, E. S. A human rights approach to an international code of conduct for genomic and clinical data sharing. Hum. Genet. 133, 895-903 (2014).
65. Lappalainen, I. et al. The European Genome-phenome Archive of human data consented for biomedical research. Nat. Genet. 47, 692-695 (2015).
66. Thompson, R. et al. RD-Connect: an integrated platform connecting databases, registries, biobanks and clinical bioinformatics for rare disease research. J. Gen. Intern. Med. 29, S780-S787 (2014).
67. Monaco, L., Crimi, M. & Wang, C. M. The challenge for a European network of biobanks for rare diseases taken up by RD-Connect. Pathobiology 81, 231-236 (2014).
68. MacArthur, D. G. et al. Guidelines for investigating causality of sequence variants in human disease. Nature 508, 469-476 (2014).
69. Di Fruscio, G., Garofalo, A., Mutarelli, M., Savarese, M. & Nigro, V. Are all the previously reported genetic variants in limb girdle muscular dystrophy genes pathogenic? Eur. J. Hum. Genet. 24, 73-77 (2015).
70. Norwood, F. L. et al. Prevalence of genetic muscle disease in Northern England: in-depth analysis of a muscle clinic population. Brain 132, 3175-3186 (2009).
71. Köhler, S. et al. The Human Phenotype Ontology project: linking molecular biology and disease through phenotype data. Nucleic Acids Res. 42, D966-D974 (2014).
72. Philippakis, A. A. et al. The Matchmaker Exchange: a platform for rare disease gene discovery. Hum. Mutat. 36, 915-921 (2015).
73. Faravelli, I., Nizzardo, M., Comi, G. P. & Corti, S. Spinal muscular atrophy - recent therapeutic advances for an old challenge. Nat. Rev. Neurol. 11, 351-359 (2015).
74. Jirka, S. & Aartsma-Rus, A. An update on RNA-targeting therapies for neuromuscular disorders. Curr. Opin. Neurol. 28, 515-521 (2015).
75. Klein, A. F., Dastidar, S., Furling, D. & Chuah, M. K. Therapeutic approaches for dominant muscle diseases: highlight on myotonic dystrophy. Curr. Gene Ther. 15, 329-337 (2015).
76. Straub, V. & Bertoli, M. Where do we stand in trial readiness for autosomal recessive limb girdle muscular dystrophies? Neuromuscul. Disord. 26, 111-125 (2016).
77. Bushby, K. Looking forward to new therapies: a personal perspective on the translational landscape for muscular dystrophies. J. Neuromuscul. Dis. 2, 83-87 (2015).
78. Bladen, C. L. et al. The TREAT-NMD Duchenne muscular dystrophy registries: conception, design, and utilization by industry and academia. Hum. Mutat. 34, 1449-1457 (2013).
79. Bladen, C. L. et al. Mapping the differences in care for 5,000 spinal muscular atrophy patients, a survey of 24 national registries in North America, Australasia and Europe. J. Neurol. 261, 152-163 (2013).
80. Walter, M. C. et al. Treatment of dysferlinopathy with deflazacort: a double-blind, placebo-controlled clinical trial. Orphanet J. Rare Dis. 8, 26 (2013).
81. Burch, P. M. et al. Muscle-derived proteins as serum biomarkers for monitoring disease progression in three forms of muscular dystrophy. J. Neuromuscul. Dis. 2, 241-255 (2015).
82. Mascalzoni, D. et al. International Charter of principles for sharing bio-specimens and data. Eur. J. Hum. Genet. 23, 721-728 (2014).